Abstract: An imbalance between bone formation and bone resorption is a factor in the development of osteoporosis. Bone turnover markers (BTM) are useful in assessing bone remodeling at the cellular level. Measurement of BTM is useful for assessing bone turnover and therefore fracture risk as well as for monitoring response to treatment response. This paper describes the steps that have been taken so far and the ongoing work to harmonize the total testing process for the assessment of bone turnover in osteoporosis internationally and collaboratively between the clinical and laboratory professions. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) in collaboration with the International Osteoporosis Foundation (IOF) as well as the National Bone Health Association (NBHA) in the US have designated procollagen type I N propeptide (s-PINP), and cross-linked β-isomerized type I collagen C-telopeptide (s-βCTX), in blood as reference standard BTM. Collaborative efforts are ongoing in order to standardize preanalytical steps as well as the analysis of s-PINP and s-CTX by standardizing or harmonizing their measurement as appropriate and reporting of values. Reporting units have been standardized. Reference interval studies and examination of appropriate decision thresholds, reference change values and treatment targets are ongoing with the aim of harmonizing the total testing process for the assessment of bone turnover in osteoporosis.
Introduction
Bone is made up of mineralized collagen matrix together with embedded bone cells (osteocytes). The amount of bone tissue in a fully grown healthy adult remains stable until around menopause in women and later in life in men. However, the bone tissue itself is not static, but is continually remodeled in discrete pockets (bone remodeling units) in response to mechanical stresses and in order to repair micro damage and fractures. Maintenance of bone mass requires the amount of bone resorbed by osteoclasts to be matched by the new bone formed by osteoblasts in each remodeling unit. If there is a deficit in the latter there is gradual bone loss over time leading to the development of osteoporosis. This process is accelerated when the deficit at each bone remodeling unit is accentuated by an increase in bone turnover rate such as occurs around menopause.
Bone turnover markers (BTM) are released during bone remodeling and are thought to reflect bone remodeling activity. Their measurement in blood or urine has been shown to be useful in assessing bone turnover, prediction of bone loss and estimating fracture risk as well as response to osteoporosis treatments. Although bone turnover can be assessed by bone biopsy and histomorphometry or radiotracer studies, these are not used in routine clinical practice due to their invasive nature and the time and effort involved. In contrast, measurement of BTM in a blood or urine sample is relative easy and non-invasive and is the preferred method for assessing bone turnover in clinical practice. The use of BTM for research and for clinical practice has developed organically, and only recently have efforts been focused on standardizing or harmonizing their use in practice. The harmonization of the total testing process for the assessment of bone turnover in osteoporosis involves the following steps [1, 2] : -Agreement on the concept and attributes of BTM -Specification of the BTM to be used for assessment of bone turnover including characterization of the measurands if 
Definition of bone turnover markers
BTM are defined as "biochemical products measured in blood or urine, and which reflect the metabolic activity of bone but which themselves have no function in controlling skeletal metabolism" [3] . They are traditionally categorized as markers of bone formation (BFM) or bone resorption (BRM). BFM are direct or indirect products of osteoblasts expressed during the different phases of osteoblast activity, reflecting different phases of bone formation and the bone formation rate [4] . BRM are degradation products of bone collagen or products of osteoclasts expressed during osteoclastic activity, reflecting the BRM rate [4] . Excluded from these definitions are bone active hormones such as parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D, vitamin D itself and also the more recently described cell signaling molecules such as osteoprotegerin, RANK ligand and sclerostin which have an important role in modulating bone remodeling and metabolism and which can be measured in blood. The earliest used BTM was hydroxyproline in urine, a collagen degradation product that is not specific to bone but is also derived from other sources such as skin [5] . Since then, a large number of "bone markers" with more or less specificity to bone collagen have been developed and tested for their clinical utility in diagnosis and monitoring of various metabolic and malignant bone diseases [6] . Many of these BTM have been included in observational studies examining their relationship to bone mineral density (BMD), menopausal bone loss and fracture risk, as well as their utility in monitoring response to treatment for osteoporosis and other bone diseases such as Paget's disease [3, 4, 7] .
Reference BTM
Whilst these studies have thrown a light on various aspects of bone disease and bone remodeling activity as well as drug action, the lack of consensus on the best markers to use in the above settings has also been counterproductive in leading to disparate practices in BTM use in observational studies and clinical trials of osteoporosis treatments, preventing the accumulation of adequate and substantial knowledge on any single BTM for their clinical use in osteoporosis. This also led to differences in recommendations for their clinical use in fracture risk assessment and in the monitoring of osteoporosis treatment. The lack of uniformity in use of BTM in observational studies and clinical trials as well as in management guidelines is in part due to the fact that there is no gold standard BTM that reflects bone remodeling with perfect sensitivity and specificity. This led to the recognition of the need for identifying 'reference BTM' with acceptable performance for such use in order to accumulate adequate information on those specified markers so that conclusions could be reached on their relationship to fracture risk in observational studies and risk reduction in clinical trials [8] . This would in turn allow their utility in fracture prediction as well in monitoring response to treatment to be determined in order for their inclusion in management algorithms and treatment guidelines.
IFCC in collaboration with the IOF formed a working group to examine the literature relevant to the application of BTM to fracture risk assessment and monitoring of treatment in order to provide recommendations on their clinical use in osteoporosis; or if there was not adequate data to make firm recommendations, a research strategy was to be formulated by the working group to move the field forward in order to arrive at a stage when recommendations could be made on clinical use of BTM in osteoporosis [3] .
The IOF-IFCC working group published their findings in 2011 [3] , which are summarized as follows:
Increased BTM may predict fracture risk independently of BMD in postmenopausal women; there is a need for more evidence for their use in clinical practice for fracture risk assessment.
BTM provide pharmacodynamic information on the response to osteoporosis treatment, but their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, lack of evidence-based thresholds for clinical decision-making and limited data for comparison of treatments using the same BTM due to inter-laboratory variation and lack of standardization of methodology.
One BFM marker in blood, s-PINP, and one BRM in blood, s-βCTX, were chosen as the reference BTM based on pre-specified performance criteria. It was recommended that s-PINP and s-CTX be measured by standardized (or harmonized) assays in all future observational and intervention studies in order to provide ability to pool studies more easily, compare the performance of alternatives and to add to the international experience of the application of BTM in clinical practice. However, this does not preclude the additional use of other BTMs in such studies.
Following the publication of the IOF-IFCC Position Paper, NBHA in the United States (USA), in collaboration with the American Association for Clinical Chemistry (AACC), published a paper endorsing s-PINP as the most promising BFM and s-CTX as the most promising BRM for use as reference markers [9] . The NBHA BTM Project aims to standardize BTM sample collection procedures in the USA, establish national reference intervals for s-PINP and s-CTX, and standardize their assays used in clinical laboratories [9] .
Harmonizing the pre-analytical phase
One of the perceived major drawbacks of BTM was considered to be their large biological variation, although this was more applicable to BTM in urine than in blood [3, 4, 9] ; hence the need to standardize sample collection procedures to minimize the effect of circadian variation as well as the effect of food on the BTM concentrations. In addition, stability of the BTM in the sample needs to be maximized. A recent Position Paper by NBHA on sample handling and patient preparation to reduce pre-analytical variability recommends that sample collection be performed in the morning in the fasting state; whilst PINP is relatively stable in serum, CTX is less so, and sample collection in EDTA is preferred in order to maximize stability for the latter [10] . More data on optimal conditions for long-term storage are required.
Assay standardization
A major step forward in the measurement and reporting of BTM will be the standardization or harmonization of their measurement as appropriate. PINP as a measurand is not fully characterized [3, 4] . The commercial immunoassays for PINP in blood recognize either the intact PINP (trimer) molecule (e.g. Immunodiagnostic Systems) or total PINP (both the intact molecule and the monomer fragment, Roche Diagnostics). Despite these differences, the two automated commercial assays for PINP give similar results in patients with normal renal function and therefore may be considered to be harmonized although this will have to be formally established [11] . On the other hand, the two automated commercial assays for s-βCTX which are both specific for the same well-characterized β-isomerized 8-amino acid peptide have a significant bias in the measured values they provide. Efforts to harmonize the commercially available s-βCTX assays are therefore currently under way [11] .
Harmonizing the post-analytical phase
The units of reporting for s-PINP and s-CTX have been agreed, and are μg/L for PINP and ng/L for CTX in order to enable the values to be reported in whole numbers [11] .
Several studies of reference intervals in women, both pre-and post-menopausal, as well as in men have been published in various populations [11] . BTM concentrations are age dependent, being higher in growing children. They are at their lowest in women in the 35-45 year age range, increasing somewhat around menopause. Use of appropriate BTM reference intervals is important for the correct interpretation of the results; efforts to establish and, where appropriate, harmonize reference values are ongoing [9, 11, 12] . More data are especially required in children in whom partitioning of reference intervals by age groups is important.
As BTM are currently not used for treatment decisions, thresholds for treatment initiation are not available. However, reference intervals may be useful to identify abnormally increased concentrations and the need for evaluation for causes of secondary osteoporosis [13] . When patients on treatment are monitored for efficacy and adherence, a change in BTM greater than the reference change value and agreed treatment targets would be useful. The IOF and European Calcified Tissue Society Working Group recommend using a value greater than the reference change value as evidence of adherence to therapy [14] . Consensus is needed on these values for s-PINP and s-CTX. The American Association of Clinical Endocrinologists and the American College of Endocrinology Guideline on osteoporosis management recommends the use of premenopausal median BTM value as a target for antiresorptive therapy [13] . The median value may vary depending on population reference intervals. In addition, as response of BTM to individual drugs varies [15] , individual treatment targets could in theory be specified for each medication. This is an evolving area which needs further work before consensus and harmonization of treatment targets based on standardized assays are reached. Similar sentiments apply with regard to thresholds used for re-institution of therapy following drug holidays [13] .
Impact of renal failure on BTM
It needs to be emphasized that the reference BTM were chosen for their potential utility in management of osteoporosis; the above mentioned activities did not examine other metabolic or metastatic bone diseases. The impact of chronic kidney disease (CKD) on BTM is well known and their use in management of osteoporosis in patients with CKD may therefore be adversely impacted [3, 9] . S-CTX and s-total PINP are both increased in CKD whilst intact PINP is not [16] . The only BTM recommended for clinical use in the management of mineral bone disease (MBD) of CKD is the BFM bone specific alkaline phosphatase [17] . Intact PINP may have potential but currently there are no data on its association with bone histomorphometry or that it in fact reflects bone formation accurately in patients with CKD-MBD [16] . Tartrate resistant acid phosphatase 5b (TRAP5b), an enzyme secreted by the osteoclast, is also unaffected by CKD or dialysis and may be a candidate BRM in such patients [16] . However, again there are no data on its ability to reflect BRM with accuracy in CKD-MBD or its clinical utility in these patients.
Conclusions
There has been significant progress made in the efforts to harmonize each of the steps in the total testing process for the assessment of bone turnover in osteoporosis. The collaborative nature of these efforts both between the laboratory and the clinical professions as well as between drivers of change from different parts of the world has been an important reason for the amount of progress achieved so far. More work is needed to complete this task, and this is ongoing collaboratively between the laboratory and clinical professions internationally [3, 9, 11] .
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